-
Mashup Score: 2Haemophilia—unparalleled progress but inadequate access - 2 year(s) ago
Haemophilia is an inherited bleeding disease estimated to affect 818 928 people worldwide in 2021. The condition can be life-threatening if an external bleed cannot be controlled or when there is an internal bleed to a vital organ. Internal bleeding around joints is the most common complication for patients, which can result in major disability and mobility issues, reducing patients’ quality of…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Increasing total body irradiation to 400 cGy substantially reduced graft failure while maintaining the safety of haploidentical bone marrow transplantation with post-transplantation cyclophosphamide. These results suggest that engraftment after haploidentical bone marrow transplantation for haemoglobinopathies is possible, and primary graft failure—the main problem previously reported—might be…
Source: The Lancet HaematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
6/ Now we have very exciting data from augmented conditioning regimens: 1. Hopkins regimen with augmented TBI @GvHD_Meade https://t.co/DxkpxCjaXd
-
-
Mashup Score: 0Thank you to The Lancet Haematology's peer reviewers in 2022 - 2 year(s) ago
Mohamed Abou-El-Enein
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
"[In 2022] we published a greater variety of content and topics than ever before... our sincere gratitude to all the reviewers (for list of reviewers see https://t.co/QI2A0PZTHq)" 📢Thank you to our 2022 reviewers and an update on #DiversityAndInclusion https://t.co/JXGJomsZqA
-
-
Mashup Score: 0Alloimmunisation against red blood cells in sickle cell disease: transfusion challenges in high-income and low-income countries - 2 year(s) ago
Sickle cell disease is the most frequent inherited disorder in sub-Saharan Africa and in many high-income countries (HICs). Transfusion is a key element of treatment, but it results in high rates of alloimmunisation against red blood cell antigens and post-transfusion haemolysis, which can be life-threatening in severe cases. The prevention of alloimmunisation is, therefore, an important issue in…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Alloimmunisation against red blood cells in people with #SickleCell disease: #transfusion challenges in high-income and low-income countries NEW Viewpoint by France Pirenne, Aline Floch & Saliou Diop #transfusionmedicine #BloodDonation https://t.co/KKo3NXlEVG https://t.co/A8e2C7F1Yj
-
-
Mashup Score: 0
Interferon alfa-2b is efficacious for treating low-grade lymphomatoid granulomatosis and hence reducing progression to high-grade disease, whereas patients with high-grade lymphomatoid granulomatosis showed expected responses to chemotherapy. Uncontrolled immune regulation of Epstein-Barr virus is hypothesised to result in the emergence of low-grade disease after chemotherapy, for which treatment…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEW online: a phase 2 trial @theNCI investigated the activity and safety of interferon alfa-2b immunotherapy in patients with low-grade and standard DA-EPOCH-R chemotherapy in patients with high-grade lymphomatoid granulomatosis #lymsm https://t.co/EHQNWYdXC5 https://t.co/N0U9gDXXNh
-
-
Mashup Score: 1A long-awaited benchmark in lymphomatoid granulomatosis - 2 year(s) ago
Infections with Epstein-Barr virus are common and usually innocuous; although some people have a syndrome known as infectious mononucleosis, most infections are asymptomatic.1 However, the virus remains latent in B lymphocytes, and if immune surveillance is compromised, Epstein-Barr virus can reactivate and cause potentially fatal lymphoproliferative disorders.1,2 An example is lymphomatoid…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
"This study is a major advancement in elucidating the natural history of lymphomatoid granulomatosis, and in establishing a standard approach for the condition" Linked commnet by Anthea Peters & Minakshi Taparia #lymsm https://t.co/RHfrERcXl2
-
-
Mashup Score: 1
In participants with haemophilia A or B without inhibitors, fitusiran prophylaxis resulted in significant reductions in annualised bleeding rate compared with on-demand clotting factor concentrates and no bleeding events in approximately half of participants. Fitusiran prophylaxis shows haemostatic efficacy in both haemophilia A and haemophilia B, and therefore has the potential to be…
Source: The Lancet HaematologyCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The study in @TheLancetHaem investigated the use of the medication in patients without inhibitors. 40 out of 79 (51%) participants given monthly injections of fitusiran experienced zero bleeds, compared to 2 out of 40 (5%) in the comparator group. https://t.co/lyp5y6L641
-
-
Mashup Score: 3
In participants with haemophilia A or B without inhibitors, fitusiran prophylaxis resulted in significant reductions in annualised bleeding rate compared with on-demand clotting factor concentrates and no bleeding events in approximately half of participants. Fitusiran prophylaxis shows haemostatic efficacy in both haemophilia A and haemophilia B, and therefore has the potential to be…
Source: The Lancet HaematologyCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
The study in @TheLancetHaem investigated the use of the medication in patients without inhibitors. 40 out of 79 (51%) participants given monthly injections of fitusiran experienced zero bleeds, compared to 2 out of 40 (5%) in the comparator group. https://t.co/lyp5y6L641
-
-
Mashup Score: 1
In participants with haemophilia A or B without inhibitors, fitusiran prophylaxis resulted in significant reductions in annualised bleeding rate compared with on-demand clotting factor concentrates and no bleeding events in approximately half of participants. Fitusiran prophylaxis shows haemostatic efficacy in both haemophilia A and haemophilia B, and therefore has the potential to be…
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Fitusiran, a subQ investigational siRNA therapeutic, shows haemostatic efficacy as prophylaxis in both #haemophilia A and B Check the results of the ATLAS A/B study https://t.co/egppH04LT7 And @TheLancet ATLAS-INH #hemophilia #bleedingdisorders https://t.co/98c94qIKKE
-
-
Mashup Score: 0Fitusiran prophylaxis in severe haemophilia without inhibitors - 2 year(s) ago
Haemophilia is a congenital X-linked bleeding disorder caused by deficiency of coagulation factors VIII (haemophilia A) or IX (haemophilia B). Recurrent joint bleeding, leading to the development of arthropathy, is the hallmark of haemophilia and is more pronounced in people with moderate to severe forms of the disease (<1–5% of normal factor VIII or IX concentrations).1 Prophylaxis is the...
Source: The Lancet HaematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
"Fitusiran... provide[s] an... alternative for both haemophilia A and B... opening the door to its use in... other severe coagulation disorders" Comment @TheLancetHaem by @vjimenezyuste & @Malvarezroman #bleedingdisorders #hemophilia https://t.co/grkNtP1hEe
-
Today marks World #Hemophilia Day! #WHD2023 🩸 To support the @wfhemophilia's campaign of “access for all: prevention of bleeds as the global standard of care” we are sharing out latest Editorial on the topic #Free to read w/reg https://t.co/F8VoMFCGsH